{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+-+Part+2&page=2",
    "query": {
      "intervention": "Treatment C - Part 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+-+Part+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T05:26:16.831Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06503978",
      "title": "Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Gastro-Intestinal Disorder",
        "Constipation",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "MTP-101P",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Vancomycin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Miralax",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Antacid",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo MTP-101P",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo Vancomycin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Gut-Brain-Axis Therapeutics Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "4 Years to 18 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-20",
      "completion_date": "2026-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06503978"
    },
    {
      "nct_id": "NCT02486406",
      "title": "A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Ombitasvir/paritaprevir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Dasabuvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Ombitasvir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Paritaprevir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Dasabuvir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-10-28",
      "completion_date": "2020-11-19",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02486406"
    },
    {
      "nct_id": "NCT00730990",
      "title": "A Phase I, Healthy Volunteer Positron Emission Tomography Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Positron Emission tomography",
          "type": "OTHER"
        },
        {
          "name": "PET Scan with PF-03654746",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2008-05",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730990"
    },
    {
      "nct_id": "NCT02278250",
      "title": "First in Human Study of M4344 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "M4344 10 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 20 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 40 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 80 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 160 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 300 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 450 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 700 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 1050 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 1200 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 100 mg BID",
          "type": "DRUG"
        },
        {
          "name": "M4344 150 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 250 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 350 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 400 mg",
          "type": "DRUG"
        },
        {
          "name": "M4344 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2015-01-26",
      "completion_date": "2021-09-24",
      "has_results": true,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 8,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278250"
    },
    {
      "nct_id": "NCT04932005",
      "title": "A Study of DZD2269 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "DZD2269",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dizal Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2021-06-29",
      "completion_date": "2022-04-12",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04932005"
    },
    {
      "nct_id": "NCT04736173",
      "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Nonsquamous Non Small Cell Lung Cancer",
        "Squamous Non Small Cell Lung Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2021-02-08",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 3,
      "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Kingwood",
          "state": "Texas"
        },
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736173"
    },
    {
      "nct_id": "NCT05037149",
      "title": "Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "STP707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sirnaomics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-11-01",
      "completion_date": "2024-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037149"
    },
    {
      "nct_id": "NCT01900431",
      "title": "Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Folic/folinic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Sarilumab)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2013-10",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-20",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 5,
      "location_summary": "Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Slingerlands",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900431"
    },
    {
      "nct_id": "NCT07222761",
      "title": "A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed and/or Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "Linvoseltamab",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 915,
      "start_date": "2026-01-02",
      "completion_date": "2034-08-23",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • New York, New York • Columbus, Ohio + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222761"
    },
    {
      "nct_id": "NCT03078556",
      "title": "Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 154,
      "start_date": "2017-03-27",
      "completion_date": "2017-08-18",
      "has_results": true,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-09-29T05:26:16.831Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078556"
    }
  ]
}